There’s much more to cannabis than THC—for solid proof, look no further than the CBD boom—but when it comes to moving product on the legal recreational market, only two numbers matter: the list price, and the THC content.
Articles
Revive Therapeutics Expands Research Partnership for Novel Formulation Development and Clinical Research of Psilocybin with University of Wisconsin-Madison
Revive expands on its psychedelics research aimed at addiction treatment.
Champignon Announces Closing of $15 Million Bought Deal Private Placement
Champignon Brands closes on a $15 million financing to expand its clinical psychedelics research programs.
Why is it so hard for medical cannabis patients to get high?
Once upon a time, I was a one-hit wonder. Just one inhale would render a dull day into one that was endlessly entertaining.
Numinus receives Health Canada licence amendment to produce and extract psilocybin from mushrooms
Numinus becomes the first publicly traded company in Canada to obtain such licensing for psychedelics research.
Will Compass Pathways Be The Next Unicorn?
As rumors swirl about Compass Pathways going public, this could become the first psychedelics Unicorn.
Study Finds Over-the-Counter CBD Products Less Potent Than Advertised
CBD-infused products that are purchased over-the-counter contain far lower percentages of cannabidiol than advertised on the products’ labeling.
Proposed Federal Police Reforms Include No-Knock Raids Ban
Congressional Democrats have put forward legislation aimed at addressing systemic racial discrimination by police that includes a ban on no-knock warrants for drug-related crimes.
Illegal status of cannabis 'a barrier to people getting support'
Illegal status of cannabis poses as a barrier to people getting support.
MindMed Begins Phase 2 Clinical Trial of LSD for Treating "Suicide Headaches"
MindMed begins a Phase 2 clinical trial of LSD for cluster headaches in Switzerland.
Study: Certain Cannabinoid Extracts May Dampen Fatal COVID-19 Symptoms
Canadian researchers suggest that certain cannabinoid extractions could help to quell an immune system response to the coronavirus that has proven fatal in some patients; the study was published as a pre-print, meaning it has not been peer-reviewed.
Champignon Identifies Synthetic Ketamine and Psilocybin/Psilicin Metabolite Targets; Selects Dalriada to Advance IP Portfolio
Champignon Brands has added a new contact research organization (CRO) to advance its IP portfolio.
Arkansas Allows Cannabis Legalization Campaign to Collect E-Signatures
Cannabis supporters in Arkansas can now accept electronic signatures in their campaign to put the legalization question on November’s ballot.
Monthly Cannabis Sales in Oregon Topped $100 Million for the First Time Ever
Oregon cannabis sales reached another milestone in May, topping $100 million for the first time since recreational use was legalized in 2015.
Hollister Biosciences Inc. Subsidiary AlphaMind Brands Inc. Plans Launch of Initial Medicinal Mushroom Based Product Line
AlphaMind Brands Inc is entering the functional mushrooms market.